drugset / Trial / NCT02916095
Kanitinib in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
9 enrolled
Beijing Konruns Pharmaceutical Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety , tolerability, pharmacokinetics of Kanitinib and determine the optimal dose in patients with recurrent or metastatic solid tumors.
Timeline
- Start
- 2016-11
- Primary completion
- 2020-01
- Completion
- 2020-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Kanitinib | Unknown | — | Oral |